Research programme: nitric oxide based therapeutics - Coeurative
Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Coeurative
- Class Antivirals; Cardiovascular therapies; Organic nitrates; Small molecules; Sugar alcohols; Urea compounds; Vasodilators
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders
- No development reported COVID 2019 infections
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA
- 15 Dec 2020 Coeurative has patent protection for the use of its compounds for the treatment of Cardiovascular disorders in USA (Coeurative website, December 2020)
- 15 Dec 2020 Coeurative has patents pending for the anti-viral properties of its compounds in USA (Coeurative website, December 2020)